{"filing":{"accession_number":"0001104659-26-076627","cik":"0000921114","ticker":"ARMP","company_name":"Armata Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"tm2618503d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926076627/tm2618503d1_8k.htm"},"events":[{"id":12977,"run_id":11519,"accession_number":"0001104659-26-076627","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Armata announced receipt of $2.5 million in additional non-dilutive Department of Defense funding for development of AP-SA02, bringing total DoD support to $28.7 million. This is a material operational and strategic event—non-dilutive funding supports Phase 3 readiness of a lead clinical candidate—but does not fit the specific categories of debt issuance, equity dilution, or other named financial/operational types. The funding is operational in nature (supporting clinical development) rather than a discrete financial obligation or capital raise.","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":9987,"accession_number":"0001104659-26-076627","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Armata announced receipt of $2.5 million in additional non-dilutive Department of Defense funding for development of AP-SA02, bringing total DoD support to $28.7 million. This is a material operational and strategic event—non-dilutive funding supports Phase 3 readiness of a lead clinical candidate—but does not fit the specific categories of debt issuance, equity dilution, or other named financial/operational types. The funding is operational in nature (supporting clinical development) rather than a discrete financial obligation or capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:11:37.817622+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9987,"accession_number":"0001104659-26-076627","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Armata announced receipt of $2.5 million in additional non-dilutive Department of Defense funding for development of AP-SA02, bringing total DoD support to $28.7 million. This is a material operational and strategic event—non-dilutive funding supports Phase 3 readiness of a lead clinical candidate—but does not fit the specific categories of debt issuance, equity dilution, or other named financial/operational types. The funding is operational in nature (supporting clinical development) rather than a discrete financial obligation or capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:11:37.817622+00:00","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-06-23"}]}